Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis.

Rheumatology (Oxford, England) - 1 Feb 2018

Pinal-Fernandez Iago, Ferrer-Fabregas Berta, Trallero-Araguas Ernesto, Balada Eva, Martínez Maria Angeles, Milisenda Jose César, Aparicio-Español Gloria, Labrador-Horrillo Moises, Garcia-Patos Vicente, Grau-Junyent Josep M, Selva-O'Callaghan Albert

Abstract excerpt

Objectives: To analyse the influence of genetic alterations and differential expression of transcription intermediary factor 1 (TIF1) genes in the pathophysiology of cancer-associated myositis (CAM). Methods: Paired blood and tumour DNA samples from patients with anti-TIF1γ-positive CAM and from controls were analysed by whole-exome sequencing for the presence of somatic mutations and loss of heterozygosity (LOH)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Case-Control Studies
Share to Exome Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Loss of Heterozygosity

Share to Muscle, Skeletal

Share to Myositis

Share to Neoplasms

Share to Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 29149307
DOI: 10.1093/rheumatology/kex413
PMCID: PMC5850766

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis.PMID 29149307Read ↗

Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis.Semantic proximity Read ↗

TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1γ positive cancer-associated dermatomyositis.Semantic proximity Read ↗

NanoString technology distinguishes anti-TIF-1γ+ from anti-Mi-2+ dermatomyositis patients.Semantic proximity Read ↗

Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in dermatomyositis patients with anti-TIF1γ autoantibodiesSemantic proximity Read ↗

Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.Semantic proximity Read ↗

Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside.Semantic proximity Read ↗

Clinical significance of myositis-specific autoantibodiesSemantic proximity Read ↗

Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor-induced myositisSemantic proximity Read ↗

Mitochondrial dysfunction and role of harakiri in the pathogenesis of myositisSemantic proximity Read ↗

Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer–myositis connectionSemantic proximity Read ↗

Expression of the Dermatomyositis Autoantigen Transcription Intermediary Factor 1γ in Regenerating MuscleSemantic proximity Read ↗

Pathogenic autoantibody internalization in myositisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.